Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
Biochemotherapy (combined immunotherapeutic drugs and chemotherapeutic drugs) has shown
virtue than that use chemical or biological drugs alone in the treatment of some malignant
tumor. Here we investigated the efficacy of sequential intravesical therapy with EPI and BCG
to EPI or BCG alone in patients with transitional cell carcinoma of bladder cancer after
surgical management.